Constellation Pharma Skyrockets More Than 100% on Promising Drug Trial Data 

Investing.com – Constellation Pharmaceuticals jumped on Wednesday after a favorable preliminary Phase 2 clinical trial for a drug treatment for patients with Myelofibrosis.

All four patients achieved at least a 35% reduction in spleen volume and at least a 50% improvement in total symptom score as early as three months after treatment, the study showed.

The drug, called MANIFEST, is expected to end its primary testing period in August 2021.

Shares of Constellation Pharmaceuticals (NASDAQ:) surged nearly 112% in midday trade.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.